We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+18.77%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$5.81B
AUM Growth
+$81.2M
Cap. Flow
-$98.4M
Cap. Flow %
-1.69%
Top 10 Hldgs %
85.45%
Holding
128
New
20
Increased
23
Reduced
35
Closed
17
Avg Time Held Equity + Options
4.5 quarters
Top 10 Avg Time Held Equity + Options
5.6 quarters
Top 20 Avg Time Held Equity + Options
4.4 quarters
Avg Time Held Equity only
5.5 quarters
Top 10 Avg Time Held Equity only
6.1 quarters
Top 20 Avg Time Held Equity only
7.1 quarters

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$7.13M
2
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$6.85M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$5.62M
4
PRQR icon
ProQR Therapeutics
PRQR
+$5.19M
5
ARRY icon
Array Biopharma Inc
ARRY
+$5.11M

Top Sells

Rank Stock Value
1
GS icon
Goldman Sachs
GS
+$22.6M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$15M
3
ONC icon
BeOne Medicines Ltd
ONC
+$13M
4
BLUE icon
bluebird bio
BLUE
+$12.4M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$12.2M

Sector Composition

Rank Sector Weight
1 Consumer Staples 42.79%
2 Consumer Discretionary 22.09%
3 Healthcare 21.97%
4 Miscellaneous 13.15%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
DMTX
101
DELISTED
Dimension Therapeutics, Inc
DMTX
$1.41M 0.02%
234,493
– –
2015 Q4
7 quarters
ATYR icon
102
aTyr Pharma
ATYR
$24.1M
$1.26M 0.02%
+17,857
New +$827K
2017 Q3
0 quarters
IBRX icon
103
ImmunityBio
IBRX
$11.1B
$1.23M 0.02%
225,000
– –
2015 Q3
8 quarters
ARGX icon
104
argenx
ARGX
$51.9B
$1.23M 0.02%
+54,337
New +$1.13M
2017 Q3
0 quarters
IMDX icon
105
Insight Molecular Diagnostics
IMDX
$110M
$1.13M 0.02%
7,500
– –
2016 Q1
6 quarters
CRBP icon
106
Corbus Pharmaceuticals
CRBP
$104M
$1.07M 0.02%
5,000
-3,333
-40% -$652K
2017 Q2
1 quarter
KRYS icon
107
Krystal Biotech
KRYS
$9.82B
$997K 0.02%
+100,000
New +$1.01M
2017 Q3
0 quarters
ARAV
108
DELISTED
Aravive, Inc. Common Stock
ARAV
$980K 0.02%
66,667
+8,334
+14% +$841K
2017 Q1
2 quarters
VRDN icon
109
Viridian Therapeutics
VRDN
$2.11B
$915K 0.02%
+6,667
New +$1.12M
2017 Q3
0 quarters
NVAX icon
110
Novavax
NVAX
$2.1B
$570K 0.01%
25,000
– –
2016 Q3
4 quarters
XENE icon
111
Xenon Pharmaceuticals
XENE
$3.53B
$443K 0.01%
150,000
– –
2017 Q1
2 quarters
ABBV icon
112
CALL
AbbVie
ABBV
$489B
– –
-500,000
Closed -$36.3M –
AGIO icon
113
CALL
Agios Pharmaceuticals
AGIO
$1.9B
– –
-100,000
Closed -$5.14M –
FCX icon
114
Freeport-McMoran
FCX
$106B
– –
-250,000
Closed -$3M –
GS icon
115
Goldman Sachs
GS
$261B
– –
-100,000
Closed -$22.6M –
IONS icon
116
Ionis Pharmaceuticals
IONS
$7.52B
– –
-135,000
Closed -$6.87M –
MET icon
117
MetLife
MET
$62.5B
– –
-112,200
Closed -$5.46M –
MSFT icon
118
CALL
Microsoft
MSFT
$3.97T
– –
-1,000,000
Closed -$68.9M –
SRPT icon
119
CALL
Sarepta Therapeutics
SRPT
$1.89B
– –
-100,000
Closed -$3.37M –
ZTO icon
120
ZTO Express
ZTO
$15.1B
– –
-500,000
Closed -$6.98M –
SGEN
121
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-75,000
Closed -$3.84M –
ATH
122
DELISTED
Athene Holding Ltd. Class A Common Shares
ATH
– –
-200,000
Closed -$9.92M –
ALXN
123
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-20,900
Closed -$2.54M –
ALXN
124
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-100,000
Closed -$12.2M –
AIMT
125
DELISTED
Aimmune Therapeutics
AIMT
– –
-100,000
Closed -$2.06M –
2 3 4
5
6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q3 2017 Portfolio in Review

As of Q3 2017, Artal Group held 128 positions worth $5.81B, up 1.4% from $5.72B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Artal Group's Q3 2017 filing shows 20 new, 23 increased, 35 reduced and 17 closed positions. Its largest new stake was Achillion Pharmaceuticals: 1,000,000 shares worth $4.49M. The largest sale was Goldman Sachs, an estimated $22.6M.

By sector, the portfolio is most concentrated in Consumer Staples at 43% of assets, up from 35% a quarter earlier, followed by Consumer Discretionary and Healthcare.

  • Artal Group's largest Q3 2017 buy was Achillion Pharmaceuticals: 1,000,000 shares worth $4.49M.
  • Artal Group added most to Clovis Oncology, Inc. in Q3 2017, an estimated $7.13M increase.
  • Artal Group's biggest Q3 2017 reduction was Agios Pharmaceuticals, cutting an estimated $15M.
  • Artal Group fully exited Goldman Sachs in Q3 2017, selling an estimated $22.6M.
  • Artal Group's ten largest holdings make up 85% of its $5.81B portfolio in Q3 2017.
  • Artal Group opened 20 new positions and closed 17 in Q3 2017.
  • Artal Group's portfolio value rose 1.4% quarter-over-quarter to $5.81B.

Based on Artal Group's 13F filing for Q3 2017, filed 8 Nov 2017.